Clinical trial · Interventional
Evaluation Study of L-T3 Utility in the Follow-up of Patients With Thyroid Cancer
L-T3 Preparation for I131 Whole Body Scintigraphy: A Randomized Controlled Trial
NCT00223158CI-TRIAL-00014211completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To compare the hypothyroid state in patients with thyroid cancer prepared either by placebo or L-T3 following L-T4 withdrawal in preparation for whole body scintigraphy. To evaluate the time needed for TSH elevation (\> 30 mUI/L) on placebo vs. L-T3.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Thyroid Cancer | Malignant Thyroid Gland Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Liothyronine | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Evaluation of the hypothyroid status by the Billewicz questionnaire.
Secondary outcomes (1)
- measure
- The time to reach an acceptable TSH elevation.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with well-differentiated thyroid cancer, with total thyroidectomy * 18 y.o. or older Exclusion Criteria: * Use of rhTSH for Whole Body Scintigraphy preparation * Non stable cardiac arrythmias * Any condition impairing TSH elevation(glucocorticoid use, hypopituitarism) * Allergy to Liothyronine * Inability to give a consent
References
Publications (0)
Data not yet available
No reference posted for this study.